Compugen Ltd. (CGEN)
NASDAQ: CGEN · Real-Time Price · USD
1.590
-0.050 (-3.05%)
At close: Nov 17, 2025, 4:00 PM EST
1.590
0.00 (0.00%)
After-hours: Nov 17, 2025, 4:10 PM EST
Compugen Revenue
Compugen had revenue of $1.89M in the quarter ending September 30, 2025, a decrease of -88.96%. This brings the company's revenue in the last twelve months to $6.90M, down -88.47% year-over-year. In the year 2024, Compugen had annual revenue of $27.86M, down -16.72%.
Revenue (ttm)
$6.90M
Revenue Growth
-88.47%
P/S Ratio
21.91
Revenue / Employee
$93,284
Employees
74
Market Cap
148.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.86M | -5.60M | -16.72% |
| Dec 31, 2023 | 33.46M | 25.96M | 346.12% |
| Dec 31, 2022 | 7.50M | 1.50M | 25.00% |
| Dec 31, 2021 | 6.00M | 4.00M | 200.00% |
| Dec 31, 2020 | 2.00M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CGEN News
- 7 days ago - Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Compugen Reports Third Quarter 2025 Results - PRNewsWire
- 13 days ago - Compugen to Participate in Stifel 2025 Healthcare Conference - PRNewsWire
- 21 days ago - Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025 - PRNewsWire
- 5 weeks ago - Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025 - PRNewsWire
- 6 weeks ago - Compugen to Present at SITC 2025 - PRNewsWire
- 2 months ago - Compugen to Present Research at the Single Cell Genomics 2025 Conference - PRNewsWire
- 2 months ago - Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire